Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

[1]  Y. Lacasse,et al.  Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. , 2016, The Lancet. Respiratory medicine.

[2]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[3]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[4]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[5]  Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning , 2015, European Respiratory Journal.

[6]  H. Ghofrani,et al.  Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.

[7]  R. Benza,et al.  Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  E. Hunsche,et al.  Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. , 2015, The American journal of managed care.

[9]  H. Ghofrani,et al.  Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[10]  Guideline on clinical investigation of medicinal products for the treatment of acute heart failure , 2015 .

[11]  A. Torbicki,et al.  Effect of macitentan on hospitalizations: results from the SERAPHIN trial. , 2015, JACC. Heart failure.

[12]  M. Humbert,et al.  The role of combination therapy in managing pulmonary arterial hypertension , 2014, European Respiratory Review.

[13]  M. Mcgoon,et al.  Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.

[14]  M. Humbert,et al.  Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.

[15]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[16]  P. Gargiulo,et al.  Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension , 2012, European Respiratory Journal.

[17]  P. Gargiulo,et al.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.

[18]  M. Humbert,et al.  Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[20]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.